284 related articles for article (PubMed ID: 30578110)
1. Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib.
Sakamoto MR; Honce JM; Lindquist DL; Camidge DR
Clin Lung Cancer; 2019 Mar; 20(2):e133-e136. PubMed ID: 30578110
[No Abstract] [Full Text] [Related]
2. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
Naito T; Shiraishi H; Fujiwara Y
Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
[TBL] [Abstract][Full Text] [Related]
3. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
Camidge DR; Kim HR; Ahn MJ; Yang JC; Han JY; Lee JS; Hochmair MJ; Li JY; Chang GC; Lee KH; Gridelli C; Delmonte A; Garcia Campelo R; Kim DW; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger SN; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S
N Engl J Med; 2018 Nov; 379(21):2027-2039. PubMed ID: 30280657
[TBL] [Abstract][Full Text] [Related]
4. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
Zhao Y; Zhang B; Wang S; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Clin Lung Cancer; 2019 Nov; 20(6):e631-e637. PubMed ID: 31362880
[TBL] [Abstract][Full Text] [Related]
5. Brigatinib versus crizotinib for ALK-positive NSCLC.
Stirrups R
Lancet Oncol; 2018 Nov; 19(11):e585. PubMed ID: 30293790
[No Abstract] [Full Text] [Related]
6. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
7. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
Camidge DR; Kim HR; Ahn MJ; Yang JCH; Han JY; Hochmair MJ; Lee KH; Delmonte A; García Campelo MR; Kim DW; Griesinger F; Felip E; Califano R; Spira A; Gettinger SN; Tiseo M; Lin HM; Gupta N; Hanley MJ; Ni Q; Zhang P; Popat S
J Clin Oncol; 2020 Nov; 38(31):3592-3603. PubMed ID: 32780660
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease.
Doménech M; Jové M; Aso S; Marín M; Nadal E
Lung Cancer; 2018 May; 119():99-102. PubMed ID: 29656760
[TBL] [Abstract][Full Text] [Related]
9. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
[TBL] [Abstract][Full Text] [Related]
10. Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient.
Hochmair M; Weinlinger C; Prosch H
Anticancer Drugs; 2019 Nov; 30(10):1058-1060. PubMed ID: 31033499
[TBL] [Abstract][Full Text] [Related]
11. First-Line Lorlatinib or Crizotinib in Advanced
Shaw AT; Bauer TM; de Marinis F; Felip E; Goto Y; Liu G; Mazieres J; Kim DW; Mok T; Polli A; Thurm H; Calella AM; Peltz G; Solomon BJ;
N Engl J Med; 2020 Nov; 383(21):2018-2029. PubMed ID: 33207094
[TBL] [Abstract][Full Text] [Related]
12. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
[TBL] [Abstract][Full Text] [Related]
13. Rapid regression of neurological symptoms in patients with metastasised ALK+ lung cancer who are treated with lorlatinib: a report of two cases.
Gafer H; de Waard Q; Compter A; van den Heuvel M
BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31345828
[TBL] [Abstract][Full Text] [Related]
14. Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Millett RL; Elkon JM; Tabbara IA
Anticancer Res; 2018 Sep; 38(9):4969-4975. PubMed ID: 30194140
[TBL] [Abstract][Full Text] [Related]
15. Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece.
Gourzoulidis G; Zisimopoulou O; Liavas A; Tzanetakos C
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):375-385. PubMed ID: 37997764
[TBL] [Abstract][Full Text] [Related]
16. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Yang J; Gong W
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
[TBL] [Abstract][Full Text] [Related]
17. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
Descourt R; Perol M; Rousseau-Bussac G; Planchard D; Mennecier B; Wislez M; Cortot A; Guisier F; Galland L; Dô P; Schott R; Dansin E; Arrondeau J; Auliac JB; Chouaid C
Lung Cancer; 2019 Oct; 136():109-114. PubMed ID: 31491676
[TBL] [Abstract][Full Text] [Related]
18. Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis.
Gaye E; Geier M; Bore P; Guilloïque M; Lucia F; Quéré G; Gouva S; Robinet G; Descourt R
Lung Cancer; 2019 Jul; 133():1-3. PubMed ID: 31200813
[TBL] [Abstract][Full Text] [Related]
19. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
Kim DW; Tiseo M; Ahn MJ; Reckamp KL; Hansen KH; Kim SW; Huber RM; West HL; Groen HJM; Hochmair MJ; Leighl NB; Gettinger SN; Langer CJ; Paz-Ares Rodríguez LG; Smit EF; Kim ES; Reichmann W; Haluska FG; Kerstein D; Camidge DR
J Clin Oncol; 2017 Aug; 35(22):2490-2498. PubMed ID: 28475456
[TBL] [Abstract][Full Text] [Related]
20. Brigatinib: New-generation ALK inhibitor for nonsmall cell lung cancer.
Umbela S; Ghacha S; Matuknauth R; Gause S; Joshee S; Deshmukh RR
Curr Probl Cancer; 2019 Dec; 43(6):100477. PubMed ID: 31109722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]